Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Dispatch.
Press releases published on May 31, 2025
Robex gibt Abschluss des Börsengangs bekannt
GlobeNewswire
·
May 31, 2025
STADT QUÉBEC, May 31, 2025 (GLOBE NEWSWIRE) -- Der westafrikanische Goldproduzent und -erschließer Robex Resources Inc („Robex“ oder das „Unternehmen“) (TSX-V: RBX) freut sich bekannt zu geben, dass das Unternehmen den Börsengang an der Australian …
Robex annonce la finalisation de son introduction en bourse
GlobeNewswire
·
May 31, 2025
QUÉBEC, 31 mai 2025 (GLOBE NEWSWIRE) -- Robex Resources Inc. (« Robex » ou la « Société ») (TSX-V : RBX), producteur et développeur aurifère ouest-africain, a le plaisir d’annoncer le succès de son introduction sur la bourse australienne (« ASX ») avec 38 …
Crypto Bubbles Come and Go: How Bitcoin Solaris’s Technology Aims for Stable, Long-Term Appreciation
GlobeNewswire
·
May 31, 2025
TALLINN, Estonia, May 31, 2025 (GLOBE NEWSWIRE) -- As Phase 5 of its limited presale nears completion, Bitcoin Solaris (BTC-S) is gaining momentum for all the right reasons. With its innovative Nova App poised for launch and over $1.2 million raised from …
ImPact Biotech Presents Interim Analysis from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at ASCO 2025
GlobeNewswire
·
May 31, 2025
– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) – – Padeliporfin VTP treatment continues to be safe and well-tolerated, …
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS…
GlobeNewswire
·
May 31, 2025
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options Latest Phase 3 SOLARIS data show no …